Table 8.

Antibiotic agent for parenteral treatment of a urinary tract infection

Antibiotic	Threptic dose	Side effect and complication	Bacterial coverage	Contraindication
Ceftriaxone	50–75 mg/kg/day IV/IM as a single dose or divided Q 12 h Do not use it in infant <6 weeks of age	Rash Induration at the site of injection diarrhea Elevated liver enzyme	E. coli P. mirabilis M. morganii P. vulgaris K. Pneumoniae
Cefotaxime	150 mg/kg/day IV/IM divided Q 6–8 h Safe to use in infant <6 weeks of age; used with ampicillin in infants aged 2–8 weeks	Rash Induration at the site of injection Diarrhea Elevated liver enzyme Nausea and vomiting
Ampicillin	100 mg/kg/day IV/IM divided Q 8 h Used with gentamicin in neonate <2 weeks of age And patient allergic to cephalosporins	Rash Diarrhea Pruritus Nausea and vomiting Fever	Enterococcus E. coli P. mirabilis
Gentamicin	Term neonates <7 days: * 3.5–5 mg/kg/dose IV Q 24 h Infants and children <5 years: * 2.5 mg/kg/dose IV Q 8 h or single daily dosing with normal renal function of 5–7.5 mg/kg/dose IV Q 24 h Children ≥5: * 2–2.5 mg/kg/dose IV Q 8 h or single daily dosing with normal renal function of 5–7.5 mg/kg/dose IV Q 24 h Monitor the kidney function	Neurotoxicity Nephrotoxicity Ototoxicity Rash	P. aeruginosa Proteus species E. coli Klebsiella
Meropenem	Sepsis: 20 mg/kg/dose IV		Multidrug resistance Gram-negative, Gram-positive, and anerobic organisms
Tazocin	50–100 mg/kg/dose IV or IM		Gram-positive, Gram-negative, anaerobic includes pseudomonas and Group B strep

M. morganii: Morganella morganii, P. aeruginosa: Pseudomonas aeruginosa, E. coli: Escherichia coli, P. mirabilis: Proteus mirabilis, P. vulgaris: Proteus vulgaris, K. Pneumoniae: Klebsiella pneumoniae, IV: Intravenous, IM: Intramuscular